Validation of Quantitative 11C-Erlotinib PET for Imaging EGFR-Mutant Lung Cancer
Description: PUBLIC HEALTH RELEVANCE: The introduction of effective targeted therapies for selected patient populations is a major advance for the treatment of non-small cell lung cancer (NSCLC), and patients with EGFR kinase domain mutations are now treated with first-line EGFR specific tyrosine kinase inhibitors (TKIs) instead of chemotherapy. However assessment of drug action and disease progression after EGFR TKI treatment is problematic, and clinical tools to evaluate drug efficacy would be extremely valuable for the management of this patient population. We have identified 11C-erlotinib as a PET radiotracer that reports interaction of the EGFR specific TKI, erlotinib, with the EGFR, and the proposed research will therefore develop 11C-erlotinib imaging as a methodology for assessing tumor responsiveness to EGFR TKIs in the setting of a clinical trial.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2015-05-19
End date: 2020-04-30
Investigator: JOSEPH N CONTESSA
Institution: YALE UNIVERSITY
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Funded outputs count: 2
Funder award ID: R01CA195493
OpenAlex ID: G1088198584